Sepsis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Sepsis Diagnostics Market By Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, And Others), By Test Type (Laboratory Testing And Point Of Care Testing), By Product Type (Assays & Reagents And Instruments & Kits), By Pathogen (Bacterial, Fungal, And Others), By End-User (Hospitals, Pathology Laboratories, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of covid-19 pandemic and a rise in the geriatric population

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030. The sepsis diagnostics market is witnessing positive growth owing to various factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products. Therefore, the market for sepsis diagnostics is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.

Sepsis Diagnostics Market Dynamics:

One of the main drivers of the sepsis diagnostics market is the increasing prevalence of the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there have been 545,226,550 confirmed cases of COVID-19 all over the world. Thus, COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is attempted to verify or check the signs of any infection or organ damage with the disease, this can boost the demand for sepsis diagnostics, which could surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Moreover, another key factor that is responsible for the growth of sepsis diagnostics is the rise in the geriatric population, as per the data published by the WHO in the year 2023, it was estimated that between the years 2015-2050 the number of citizens who aged 60 years and above will get doubled from 12-22% and will reach 2.1 billion by the year 2050. Adding to it, by the year 2030, one out of every six individuals worldwide will age 60 years or more. As per the above-mentioned data, the number of citizens aged 80 years or over is expected to get triple between the years 2020 and 2050 & will reach 426 million population. Furthermore, as age increases chances of suffering from infections also increase due to weakening immune systems which can boost the demand for sepsis diagnosis. Therefore, the rising geriatric population increases the demand for sepsis diagnostics, this surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Therefore, the aforementioned factors could increase the demand for sepsis diagnostics, which can surge the growth of the overall sepsis diagnostics market during the forecast period from 2024-2030.

However, the high cost of sepsis treatment and the lack of awareness & knowledge about sepsis can hamper the global sepsis diagnostics market growth.

The ongoing COVID-19 epidemic has slightly positively impacted the sepsis diagnostics market. According to the Global Sepsis Alliance, SARS-CoV-2 causes sepsis. This is reinforced by a recent study, which found that viral sepsis is the most common complication in COVID-19 patients and is linked to increased mortality. Since, COVID-19 affects the patient's respiratory system, with the majority of patients requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Thus, the surge in COVID-19 pandemic cases boosted the demand for sepsis diagnostics, and the further increase in the COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in the surge in sepsis diagnostics overall market.

Sepsis Diagnostics Market Segment Analysis:

Sepsis Diagnostics Market by Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, and Others), Test Type (Laboratory Testing and Point Of Care Testing), Product Type (Assays & Reagents, Instruments & Kits), Pathogen (Bacterial, Fungal, and Others), End-User (Hospitals, Pathology Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the sepsis diagnostics market, the instruments & kits segment is expected to show significant growth during the forecast from 2024-2030. For instance, the Blood Culture Identification Panel (BCID), allows for the quick as well as precise identification of pathogens and antibiotic resistance genes associated with bloodstream infections. It looks for a wide range of pathogens (24) as well as 3 antibiotic resistance genes linked to bloodstream infections. Moreover, in roughly an hour, with only 2 minutes of hands-on work, it helps to identify infections in 9 out of 10 positive blood cultures with just one test. Thus, the benefits associated with the BCID, uplift the instruments & kits demand in the market, which could drive the growth of the overall global sepsis diagnostics market during the forecast period.

Furthermore, the developments in sepsis diagnostics products, are also expected to drive the market growth for it. For instance, in May 2022, BioMerieux, a global pioneer in-vitro diagnostics player, gained clearance from Health Canada for its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. In comparison to the original BIOFIRE® BCID Panel, the BIOFIRE® BCID2 Panel for quick molecular diagnosis of bloodstream infection contains numerous more pathogens, an extended list of antibiotic resistance genes, and many altered targets.

Hence, due to the interplay of the factors mentioned above, the sepsis diagnostics demand increases in the market, which can drive the growth of the global sepsis diagnostics market during the forecast period.

North America is expected to dominate the overall Sepsis Diagnostics Market:

Among all the regions, North America is expected to dominate the global sepsis diagnostics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the increasing prevalence of bacterial infections such as tuberculosis and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products are expected to increase the demand for sepsis diagnostics in the North America market.

According to the Centers for Disease Control and Prevention (CDC) published data in the year 2023, in the year 2023, the number of Tuberculosis (TB) cases in the United States was 7,860 which is equivalent to 2.4 per 100,000 persons. Thus, tuberculosis could lead to sepsis shock, which can result in improved demand for sepsis diagnostics, contributing to the conductive growth for sepsis diagnostics overall market forecast from 2024-2030.

Moreover, the surge in regulatory approvals for technologically advanced sepsis diagnostics products can boost the sepsis diagnostics overall market in the region. For instance, in February 2022, Noninvasix, which is expected to be the first company to non-invasively monitor central venous oxygenation announced that its LIVOx(TM) Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock in the United States.

Therefore, with the interplay of the factors mentioned above, there will be high demand for sepsis diagnostics, which would provide a conducive growth environment for the North American region in the sepsis diagnostics market.

Sepsis Diagnostics Market Key Players:

Some of the key market players operating in the sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

Recent Developmental Activities in the Sepsis Diagnostics:

In January 2022, Pathogenomix, a next-generation sequencing, pathogen diagnostic company, was granted US Food and Drug Administration (FDA) Breakthrough Device Designation for its Patho-Seq assay. The assay is designed for the quick detection and identification of hundreds of clinically important bacteria for a wide range of clinical diseases and sample types, including sepsis from whole blood samples and bacterial meningitis from Cerebrospinal Fluid (CSF).

In November 2022, Immunexpress Inc, a molecular diagnostic company focusing on improving outcomes for suspected sepsis patients, announced that SeptiCyte RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). In hospitalized patients suspected of sepsis, the approved test helps to distinguish sepsis from infection-free systemic inflammation.

In March 2020, Immunexpress, Inc., a molecular diagnostics company focusing on improving outcomes for patients with suspected sepsis, announced that SeptiCyte® RAPID, their host response technology, has achieved CE Marking. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla platform to provide actionable data in less than an hour, which allows doctors to make better patient care decisions. SeptiCyte® RAPID is a gene expression test that quantifies the relative expression levels of host response genes extracted from whole blood collected in the PAXgene® Blood RNA Tube using reverse transcription-polymerase chain reaction (PCR).

Key Takeaways from the Sepsis Diagnostics Market Report Study

• Market size analysis for current sepsis diagnostics market (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the sepsis diagnostics market
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint venture happened over the last 3 years
• Key companies dominating the global sepsis diagnostics
• Various opportunities available for the other competitor in the sepsis diagnostics market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current sepsis diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for sepsis diagnostics market growth in the coming future?

Target Audience who can be benefited from this Sepsis Diagnostics Market Report Study

• Sepsis diagnostics providers
• Research organizations and consulting companies
• Sepsis Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in sepsis diagnostics
• Various end-users who want to know more about the sepsis diagnostics market and latest technological developments in the sepsis diagnostics

Frequently Asked Questions for Sepsis Diagnostics:

1. What are Sepsis Diagnostics?

Sepsis diagnostics includes instruments, lab tests, various technologies, and others, which are used to diagnose sepsis by checking signs of infection or organ damage within the patient.

2. What is the market for Global Sepsis Diagnostics?

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030.

3. What are the drivers for the Global Sepsis Diagnostics Market?

The sepsis diagnostics market is witnessing positive market growth owing to the factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products

4. Who are the key players operating in the Sepsis Diagnostics Market?

Some of the key market players operating in the Sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

5. Which region has the highest share in Sepsis Diagnostics Market?

North America is expected to dominate the global sepsis diagnostics market. Factors contributing to the growth are the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products contributes to the growth of the sepsis diagnostics market in the North America region.